Stromal Reprogramming through Dual PDGFRa/b Blockade Boosts the Efficacy of Anti–PD-1 Immunotherapy in Fibrotic Tumors

2022年12月21日，在《CANCER RESEARCH》上發表的論文，標題為：
“Stromal Reprogramming through Dual PDGFRa/b Blockade Boosts the Efficacy of Anti–PD-1 Immunotherapy in Fibrotic Tumors”

使用締一生物國內總代理的德國MB Zell Shield^? (MB, Cat#13-0050)